Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)

BACKGROUND AND OBJECTIVES: Azithromycin was rapidly adopted as a repurposed drug to treat coronavirus disease 2019 (COVID-19) early in the pandemic. We aimed to evaluate its efficacy in patients hospitalised for COVID-19. METHODS: In a series of randomised, open-label, phase 2 proof-of-concept, mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyselinck, Iwein, Liesenborghs, Laurens, Belmans, Ann, Engelen, Matthias M., Betrains, Albrecht, Van Thillo, Quentin, Nguyen, Pham Anh Hong, Goeminne, Pieter, Soenen, Ann-Catherine, De Maeyer, Nikolaas, Pilette, Charles, Papleux, Emmanuelle, Vanderhelst, Eef, Derweduwen, Aurélie, Alexander, Patrick, Bouckaert, Bernard, Martinot, Jean-Benoît, Decoster, Lynn, Vandeurzen, Kurt, Schildermans, Rob, Verhamme, Peter, Janssens, Wim, Vos, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801156/
https://www.ncbi.nlm.nih.gov/pubmed/35233389
http://dx.doi.org/10.1183/23120541.00610-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801156/
https://www.ncbi.nlm.nih.gov/pubmed/35233389
http://dx.doi.org/10.1183/23120541.00610-2021

Ejemplares similares